Comparative Efficacy of Parenteral and Mucosal Recombinant Probiotic Vaccines Against SARS-CoV-2 and S. pneumoniae Infections in Animal Models.

IF 5.2 3区 医学 Q1 IMMUNOLOGY Vaccines Pub Date : 2024-10-19 DOI:10.3390/vaccines12101195
Galina Leontieva, Tatiana Kramskaya, Tatiana Gupalova, Elena Bormotova, Yulia Desheva, Dmitry Korzhevsky, Olga Kirik, Irina Koroleva, Sergey Borisevitch, Alexander Suvorov
{"title":"Comparative Efficacy of Parenteral and Mucosal Recombinant Probiotic Vaccines Against SARS-CoV-2 and <i>S. pneumoniae</i> Infections in Animal Models.","authors":"Galina Leontieva, Tatiana Kramskaya, Tatiana Gupalova, Elena Bormotova, Yulia Desheva, Dmitry Korzhevsky, Olga Kirik, Irina Koroleva, Sergey Borisevitch, Alexander Suvorov","doi":"10.3390/vaccines12101195","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The accumulation of specific IgG antibodies in blood serum is considered a key criterion for the effectiveness of vaccination. For several vaccine-preventable infections, quantitative indicators of the humoral response have been established, which, when reached, provide a high probability of protection against infection. The presence of such a formal correlate of vaccine effectiveness is crucial, for example, in organizing preventive measures and validating newly developed vaccines. However, can effective protection against infection occur when the level of serum antibodies is lower than that provided by parenteral vaccination? Will protection be sufficient if the same vaccine antigen is administered via mucosal membranes without achieving high levels of specific IgG circulating in the blood?</p><p><strong>Methods: </strong>In this study, we compared the immunogenicity and protective efficacy of parenteral and mucosal forms of vaccines in experimental animals, targeting infections caused by the SARS-CoV-2 coronavirus and <i>Streptococcus pneumoniae</i>. We investigated the protective properties of a fragment of the coronavirus S1 protein administered intramuscularly with an adjuvant and orally as part of the probiotic strain <i>Enterococcus faecium</i> L3 in a Syrian hamster model. A comparative assessment of the immunogenicity and protective efficacy of a recombinant tandem (PSP) of immunogenic peptides from <i>S. pneumoniae</i> surface proteins, administered either parenterally or orally, was performed in a Balb/c mouse model.</p><p><strong>Results: </strong>Both models demonstrated significant differences in the immunogenicity of parenteral and oral vaccine antigens, but comparable protective efficacy.</p>","PeriodicalId":23634,"journal":{"name":"Vaccines","volume":null,"pages":null},"PeriodicalIF":5.2000,"publicationDate":"2024-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11512341/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccines","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/vaccines12101195","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The accumulation of specific IgG antibodies in blood serum is considered a key criterion for the effectiveness of vaccination. For several vaccine-preventable infections, quantitative indicators of the humoral response have been established, which, when reached, provide a high probability of protection against infection. The presence of such a formal correlate of vaccine effectiveness is crucial, for example, in organizing preventive measures and validating newly developed vaccines. However, can effective protection against infection occur when the level of serum antibodies is lower than that provided by parenteral vaccination? Will protection be sufficient if the same vaccine antigen is administered via mucosal membranes without achieving high levels of specific IgG circulating in the blood?

Methods: In this study, we compared the immunogenicity and protective efficacy of parenteral and mucosal forms of vaccines in experimental animals, targeting infections caused by the SARS-CoV-2 coronavirus and Streptococcus pneumoniae. We investigated the protective properties of a fragment of the coronavirus S1 protein administered intramuscularly with an adjuvant and orally as part of the probiotic strain Enterococcus faecium L3 in a Syrian hamster model. A comparative assessment of the immunogenicity and protective efficacy of a recombinant tandem (PSP) of immunogenic peptides from S. pneumoniae surface proteins, administered either parenterally or orally, was performed in a Balb/c mouse model.

Results: Both models demonstrated significant differences in the immunogenicity of parenteral and oral vaccine antigens, but comparable protective efficacy.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
肠外和黏膜重组益生菌疫苗对动物模型 SARS-CoV-2 和肺炎双球菌感染的疗效比较
背景:血清中特异性 IgG 抗体的积累被认为是疫苗接种效果的关键标准。对于几种疫苗可预防的感染,已经建立了体液反应的定量指标,一旦达到这些指标,就很有可能对感染起到保护作用。这种疫苗有效性的正式相关指标对于组织预防措施和验证新开发的疫苗至关重要。然而,当血清抗体水平低于肠外疫苗接种所提供的水平时,能否有效预防感染?如果通过粘膜接种相同的疫苗抗原,而血液中循环的特异性 IgG 水平不高,是否就能提供足够的保护?在本研究中,我们以 SARS-CoV-2 冠状病毒和肺炎链球菌引起的感染为目标,比较了肠外疫苗和粘膜疫苗在实验动物中的免疫原性和保护效力。我们在叙利亚仓鼠模型中研究了冠状病毒 S1 蛋白片段与佐剂一起肌肉注射以及作为益生菌株粪肠球菌 L3 的一部分口服的保护特性。在 Balb/c 小鼠模型中,对来自肺炎双球菌表面蛋白的免疫原性肽重组串联(PSP)的免疫原性和保护效力进行了比较评估:结果:两种模型均显示肠外和口服疫苗抗原的免疫原性存在显著差异,但保护效力相当。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Vaccines
Vaccines Pharmacology, Toxicology and Pharmaceutics-Pharmacology
CiteScore
8.90
自引率
16.70%
发文量
1853
审稿时长
18.06 days
期刊介绍: Vaccines (ISSN 2076-393X) is an international, peer-reviewed open access journal focused on laboratory and clinical vaccine research, utilization and immunization. Vaccines publishes high quality reviews, regular research papers, communications and case reports.
期刊最新文献
Impact of Infections During Pregnancy on Transplacental Antibody Transfer. Interferon Epsilon-Mediated Antiviral Activity Against Human Metapneumovirus and Respiratory Syncytial Virus. Comparative Analysis of the Neutralizing Capacity of Monovalent and Bivalent Formulations of Betuvax-CoV-2, a Subunit Recombinant COVID-19 Vaccine, Against Various Strains of SARS-CoV-2. Identifying System-Level Strategies to Engage in HPV Prevention Across Oral Health and Primary Care Settings. Comparative Efficacy of Parenteral and Mucosal Recombinant Probiotic Vaccines Against SARS-CoV-2 and S. pneumoniae Infections in Animal Models.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1